Skip to content

In the BioHarmony Drug Report Database

Golimumab

Simponi, Simponi Aria (golimumab) is an antibody pharmaceutical. Golimumab was first approved as Simponi on 2009-04-24. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. The pharmaceutical is active against tumor necrosis factor.
Trade Name Simponi
Common Name Golimumab
Indication ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
Drug Class Monoclonal antibodies
Golimumab
Get full access now